COMPARISON OF SERUM URIC ACID LEVELS AMONG PATIENTS ON SGLT2 INHIBITORS AND THOSE NOT ON SGLT2 INHIBITORS.
Keywords:
Type 2 Diabetes Mellitus, SGLT2 inhibitors, Serum Uric acid levels.Abstract
Background: SGLT2 are exclusively expressed in kidneys, especially in early proximal tubule and promotes reabsorption of 80-90% of glucose filtered by glomerulus. Uric acid is a weak acid generated from the metabolism of purine and that high circulating uric acid levels may increase risk of type 2 diabetes, metabolic syndromes. SGLT2 inhibitors has demonstrated an effect in reducing serum urate levels among patients with type 2 diabetes mellitus.
References
1. Yip ASY, Leong S, Teo YH, Teo YN, Syn NLX, See RM, et al. Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. TherAdv Chronic Dis. 2022; 13: 1-17.
2. Yuan T, Liu S, Dong Y, Fu Y, Tang Y, Zhao W. Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: A prospective pilottrial. DiabetolMetaabSyndr. 2020; 12(92): 1-9.
